Overview

* Canopy Growth ( CGC ) Q2 FY2026 revenue grows 6% yr/yr, missing analyst expectations

* Adjusted EBITDA loss improves to C$3 mln in Q2 FY2026

* Canada adult-use cannabis revenue up 30% in Q2 FY2026

Outlook

* Company expects Canada adult-use cannabis growth in H2 FY2026

* Company anticipates improved European supply chain by FY2026 end

* Storz & Bickel revenue growth expected in Q3 FY2026

Result Drivers

* CANADA ADULT-USE GROWTH - Revenue up 30% driven by growth in infused pre-roll joints and new vapes from Tweed and 7ACRES

* MEDICAL CANNABIS GROWTH - Revenue up 17% due to more insured patients and larger order sizes

* INTERNATIONAL CHALLENGES - Revenue down 39% due to supply chain issues in Europe

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss C$67 mln C$70.88

Revenue mln (4

Analysts

)

Q2 -C$3 mln

Adjusted

EBITDA

Q2 Gross 33.00%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Canopy Growth Corp ( CGC ) is C$2.00, about 22.5% above its November 6 closing price of C$1.55

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)